Valuation: CS Diagnostics Corp.

Market Cap 8.92M 7.83M 7.21M 6.75M 12.66M 842M 12.93M 86.7M 33.55M 416M 33.51M 32.78M 1.44B P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 8.92M 7.82M 7.21M 6.75M 12.65M 841M 12.92M 86.63M 33.52M 416M 33.49M 32.76M 1.44B EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 week-5.80%
Current month-42.42%
1 month-63.53%
3 months-73.77%
6 months-82.24%
Current year-88.33%
1 week 0.03
Extreme 0.0345
0.04
1 month 0.03
Extreme 0.0345
0.08
Current year 0.03
Extreme 0.0345
0.4
1 year 0.03
Extreme 0.0345
0.4
3 years 0.02
Extreme 0.0215
6.25
5 years 0.02
Extreme 0.0215
9.2
10 years 0.02
Extreme 0.0215
28.95
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2022
Director of Finance/CFO 47 01/01/2022
Corporate Officer/Principal 45 18/07/2024
Director TitleAgeSince
Chairman 56 25/09/1996
Director/Board Member 47 01/01/2022
Director/Board Member 54 01/09/2025
Date Insider Type Main position Quantity % Market Cap.
12-31Other

Chief Executive Officer

42,560,096 30.9888%
12-31Other

Chief Executive Officer

104,507,800 76.0941%
12-31Other

Chief Executive Officer

49,362,500 35.9418%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.80%-51.76%-98.02% 8.92M
+0.94%+6.46%-29.96%-12.54% 164B
+1.48%+2.07%-5.86%-6.23% 104B
-0.29%+5.26%-4.44%+50.82% 55.67B
-0.23%-5.43%+48.70%+51.04% 52.92B
+3.00%+8.29%-8.74%-39.80% 42.96B
+2.91%+8.15% - - 32.87B
+2.17%-3.22%-18.75%-44.52% 27.07B
+1.24%+6.98%+60.30%-4.97% 24.79B
+2.41%+6.45%-9.68%-0.56% 21.02B
Average +1.36%+3.43%-2.24%-11.64% 52.49B
Weighted average by Cap. +1.22%+3.98%-5.65%-0.45%

Financials

2024 2025
Net sales 111K 97.25K 89.64K 83.92K 157K 10.46M 161K 1.08M 417K 5.17M 416K 407K 17.93M 204K 179K 165K 154K 289K 19.24M 295K 1.98M 767K 9.51M 766K 749K 32.98M
Net income 761 667.24 615.05 575.81 1.08K 71.79K 1.1K 7.39K 2.86K 35.48K 2.86K 2.8K 123K 71.22K 62.44K 57.56K 53.89K 101K 6.72M 103K 692K 268K 3.32M 267K 262K 11.51M
Net Debt -501 -439.28 -404.91 -379.08 -710.84 -47.26K -725.6 -4.87K -1.88K -23.36K -1.88K -1.84K -80.99K -6.81K -5.97K -5.51K -5.16K -9.67K -643K -9.87K -66.18K -25.61K -318K -25.58K -25.02K -1.1M
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
25/06/26 $0.0357 0.00% 600
24/06/26 $0.0357 +3.43% 1,000
23/06/26 $0.0345 -8.81% 2,141,236
  1. Stock Market
  2. Stocks
  3. CSDX Stock